Red Glead Discovery welcomes new Director for Drug Discovery

Mar 13, 2024

Red Glead Discovery is happy to announce the appointment of Malene Bertelsen as Director for Drug Discovery, leading the cross-functional drug discovery department. Malene has extensive pharmaceutical industry experience from management as well as from project leadership and scientist roles. With her in-depth knowledge from target validation and drug screening to early clinical development, she brings invaluable expertise into the company.  

Malene Bertelsen holds a PhD from the William Harvey Research Institute, Queen Mary University London followed up with postdoctoral studies at AstraZeneca R&D Lund. Moreover, during her long tenure at LEO Pharma she has worked with in vitro and ex vivo biology/molecular pharmacology, in vivo biology, biomarkers and translational science. She has been a key player in setting up the pharmacokinetic/pharmacodynamic capabilities at LEO Pharma. In essence, Malene has a broad scientific background from inflammatory, immunologic, and neoplastic disorders and demonstrated experience advancing several drug molecules past the IND stage. 

Her focus, in this important operational and strategic leadership role at Red Glead Discovery, will be in-line with the strategy and long-term goals of the company. This means that she will focus on the development of people as well as on our drug discovery capabilities and processes. 

Johan Evenäs, CEO at Red Glead Discovery summarises: “I foresee that Malene will be an excellent leader. She has the right combination of people-focused leadership, positive energy, and vast drug discovery experience. This will boost our journey towards being the leading company in Northern Europe within the area of innovative and sustainable drug discovery.”.

For more information, please contact:

Johan Evenäs, CEO, Red Glead Discovery AB

Telephone: +46 (0)72 328 12 92, email: